IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08/07	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
01/07	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI

Market Cap	192M 19.77M 17.33M 16.02M 14.73M 27.8M 1.91B 28.24M 75.08M 933M 74.24M 72.62M 3.21B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	192M 19.77M 17.33M 16.02M 14.73M 27.8M 1.91B 28.24M 75.08M 933M 74.24M 72.62M 3.21B	EV / Sales 2026 *	1.88x	EV / Sales 2027 *	1.35x
Free-Float	38.17%	Yield 2026 *	-	Yield 2027 *	-

08/07	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
01/07	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI
30/06	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln	RE
30/06	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering	MT
30/06	Irlab rights issue oversubscribed	FW
16/06	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
16/06	Irlab highlights positive data for mesdopetam	FW
08/06	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06/06	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
06/06	Irlab rights issue now 91 percent secured	FW
06/05	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
06/05	Irlab reports growth in revenue and operating profit	FW
06/05	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

04/11	Redeye Lowers Fair Value for Irlab to 12 Kronor (from 17)	FW
13/05/24	Irlab rises almost double-digit - Redeye raises motivated value	FW
13/05/24	Redeye raises motivated value for Irlab to SEK 40 (35)	FW
12/02/24	Edison lowers motivated value for Irlab	FW
31/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

IRLAB Therapeutics AB Stock OTC Markets

Stocks

IRLA.F

SE0012675361

Pharmaceuticals

Valuation: IRLAB Therapeutics AB

Latest news : IRLAB Therapeutics AB

Last Transcript: IRLAB Therapeutics AB

Analysts' recommendations: IRLAB Therapeutics AB

Press Releases: IRLAB Therapeutics AB

News in other languages: IRLAB Therapeutics AB

Managers and Directors: IRLAB Therapeutics AB

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

10/07	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
01/07	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
16/06	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
16/06	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
06/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ

Manager	Title	Age	Since
Kristina Torfgård CEO	Chief Executive Officer	63	01/08/2024
Susanna Waters PRN	Corporate Officer/Principal	60	01/01/2013
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	01/01/2016

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	01/01/2016
Gunnar Olof Olsson CHM	Chairman	73	07/05/2020
Carola Elisabet Lemne CHM	Chairman	68	20/02/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRLAB THERAPEUTICS AB	-.--%	-.--%	-	-	19.87M
ELI LILLY AND COMPANY	-1.36%	-1.35%	+52.98%	+151.38%	1,051B
JOHNSON & JOHNSON	-1.21%	-2.72%	+52.56%	+48.92%	609B
ABBVIE INC.	-0.46%	+2.24%	+37.17%	+78.32%	450B
ROCHE HOLDING AG	-0.75%	+0.30%	+29.77%	+21.15%	330B
NOVARTIS AG	-1.52%	-1.19%	+34.46%	+35.35%	284B
ASTRAZENECA PLC	-1.70%	-1.82%	+20.99%	+15.74%	263B
NOVO NORDISK A/S	-0.58%	+1.11%	-20.18%	-40.59%	223B
AMGEN INC.	-0.07%	+1.71%	+23.91%	+57.19%	198B
GILEAD SCIENCES, INC.	-0.36%	+1.95%	+23.72%	+67.58%	167B
Average	-0.74%	+0.54%	+28.38%	+48.34%	397.23B
Weighted average by Cap.	-0.98%	+0.02%	+37.41%	+72.40%

	2026 *	2027 *
Net sales	102M 10.53M 9.23M 8.53M 7.85M 14.8M 1.02B 15.04M 39.98M 497M 39.54M 38.67M 1.71B	142M 14.64M 12.83M 11.86M 10.91M 20.58M 1.41B 20.91M 55.59M 691M 54.96M 53.76M 2.38B
Net income	-32.6M -3.37M -2.95M -2.73M -2.51M -4.73M -324M -4.81M -12.78M -159M -12.64M -12.36M -547M	33.3M 3.44M 3.01M 2.78M 2.56M 4.83M 331M 4.91M 13.05M 162M 12.91M 12.63M 559M
Net Debt	-	-